Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 30 full-time employees. The company went IPO on 2021-01-11. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
Dr. Henry Ji est le Executive Chairman of the Board de Scilex Holding Co, il a rejoint l'entreprise depuis 2022.
Quelle est la performance du prix de l'action SCLX ?
Le prix actuel de SCLX est de $9.5, il a diminué de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Scilex Holding Co ?
Scilex Holding Co appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quel est la capitalisation boursière de Scilex Holding Co ?
La capitalisation boursière actuelle de Scilex Holding Co est de $80.6M
Est-ce que Scilex Holding Co est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Scilex Holding Co, y compris 0 achat fort, 0 achat, 3 maintien, 1 vente et 0 vente forte
